Dear Investors,

Frenelle is developing next-generation long-acting injectable therapeutics using its proprietary Faros™ drug-delivery platform. Its lead program, FRN01, is a 30-day subcutaneous buprenorphine injection being developed for Opioid Use Disorder.

​Join Opus8 and New York Private Equity Forums (NYPEF) for an exclusive investor briefing to learn more about Frenelle’s technology, development progress, and investment opportunity.

​Why Investors Are Taking Notice

​Large, Underpenetrated Market — The global long-acting injectable buprenorphine market exceeded $1.2B in 2025, yet remains underpenetrated.

​Differentiated Approach — FRN01 is designed to deliver monthly treatment while addressing key patient and access barriers.

​Promising Development Progress — FRN01 has demonstrated formulation proof of concept and encouraging PK and toxicology results.

​Experienced Team & Platform — Frenelle combines pharmaceutical development expertise with Mayo Clinic collaboration and a platform with broader therapeutic potential.